precision-oncology

Analyze cancer and tumor intelligence to build precision oncology reports.

33|7|Updated Mar 19, 2026
One-click install
npx skills add https://github.com/patsnap/skills --skill precision-oncology
Or copy as Structured Prompt for Agent
Please help me install this Agent Skill.
Skill: precision-oncology
Source: https://github.com/patsnap/skills/tree/main/life-sciences/precision-oncology
Command: npx skills add https://github.com/patsnap/skills --skill precision-oncology

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

This Skill helps you understand a cancer indication end to end by combining biology, epidemiology, treatment standards, and clinical evidence into a decision-ready oncology analysis.

Core Features & Use Cases

  • Mechanism Review: Explains tumor development, molecular drivers, and histological changes behind carcinogenesis.
  • Clinical Landscape: Summarizes incidence, patient populations, standard of care, efficacy, safety, and treatment lines.
  • Pipeline Assessment: Evaluates promising therapies, ongoing trials, unmet medical needs, and commercial viability for a cancer type.
  • Use Case: Use it when you need to compare breast cancer therapies, assess CAR-T progress in pancreatic cancer, or estimate the market opportunity for glioblastoma treatment.

Quick Start

Ask the skill to analyze a specific cancer indication and produce a structured report on its biology, epidemiology, current therapies, clinical trials, and unmet needs.

Frequently Asked Questions about precision-oncology

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I build a precision oncology report for a specific cancer indication?

To build a precision oncology report, analyze cancer intelligence spanning molecular biology, histology, epidemiology, standard of care, clinical trials, and commercial evidence to produce a structured drug strategy assessment for the target indication.

What is the best way to assess unmet medical needs and clinical trial progress for hematologic malignancies?

Assessing unmet medical needs and trial progress involves evaluating ongoing clinical trials, standard of care efficacy, and commercial viability across hematologic malignancies to identify therapeutic gaps and pipeline opportunities.

Can I compare treatment sequencing and standard of care therapies across different solid tumors?

Yes, you can compare treatment sequencing and standard of care across solid tumors by retrieving integrated clinical evidence, efficacy data, and safety profiles to evaluate therapeutic strategies and disease incidence.

How does molecular biology and biomarker evidence integrate into cancer drug development strategy?

Molecular biology and biomarker evidence integrate into drug development strategy by mapping molecular drivers and histological changes behind carcinogenesis to identify viable targets and assess commercial market opportunities.

Does this oncology analysis require retrieving clinical trials, patents, and company data to evaluate commercial viability?

Yes, evaluating commercial viability requires integrated retrieval of patents, literature, news, drugs, targets, clinical trials, and company data to form structured evidence and actionable conclusions for the cancer indication.